IRIS
STAGNO, Fabio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.151
AS - Asia 1.793
NA - Nord America 1.396
SA - Sud America 473
Continente sconosciuto - Info sul continente non disponibili 276
AF - Africa 60
OC - Oceania 4
Totale 6.153
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 1.615
US - Stati Uniti d'America 1.283
SG - Singapore 723
CN - Cina 386
BR - Brasile 382
HK - Hong Kong 262
IT - Italia 234
VN - Vietnam 144
BD - Bangladesh 93
DE - Germania 80
FR - Francia 61
IN - India 46
MX - Messico 39
CA - Canada 35
GB - Regno Unito 34
AR - Argentina 31
NL - Olanda 25
AT - Austria 23
TR - Turchia 21
ZA - Sudafrica 18
IQ - Iraq 16
ID - Indonesia 14
FI - Finlandia 13
PL - Polonia 13
EC - Ecuador 12
CO - Colombia 11
JP - Giappone 11
TN - Tunisia 11
PE - Perù 10
PK - Pakistan 10
UA - Ucraina 10
VE - Venezuela 10
CL - Cile 9
JM - Giamaica 9
MA - Marocco 9
MY - Malesia 9
SE - Svezia 8
PH - Filippine 7
AZ - Azerbaigian 6
CR - Costa Rica 6
ES - Italia 6
HN - Honduras 6
UZ - Uzbekistan 6
EG - Egitto 5
PT - Portogallo 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
DZ - Algeria 4
IL - Israele 4
PA - Panama 4
SA - Arabia Saudita 4
TT - Trinidad e Tobago 4
AU - Australia 3
DO - Repubblica Dominicana 3
GE - Georgia 3
IE - Irlanda 3
JO - Giordania 3
KE - Kenya 3
LT - Lituania 3
NP - Nepal 3
BE - Belgio 2
BG - Bulgaria 2
BN - Brunei Darussalam 2
CI - Costa d'Avorio 2
EE - Estonia 2
GT - Guatemala 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LK - Sri Lanka 2
PY - Paraguay 2
QA - Qatar 2
RO - Romania 2
SN - Senegal 2
SV - El Salvador 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
BJ - Benin 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
CM - Camerun 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
ET - Etiopia 1
HU - Ungheria 1
KH - Cambogia 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
NI - Nicaragua 1
NR - Nauru 1
PR - Porto Rico 1
PS - Palestinian Territory 1
Totale 5.874
Salva come PNG Salva come JPEG
Città #
Moscow 486
Singapore 368
Hong Kong 260
Ashburn 178
Council Bluffs 161
San Jose 143
Beijing 115
Ho Chi Minh City 59
Los Angeles 58
Messina 53
Santa Clara 51
New York 47
São Paulo 37
Dallas 30
Hanoi 29
Munich 26
Guangzhou 23
Milan 23
Mexico City 22
Columbus 21
Nuremberg 21
Rome 21
Chicago 18
Frankfurt am Main 18
Orem 17
Vienna 17
Atlanta 16
Buffalo 15
Rio de Janeiro 15
Amsterdam 14
Lauterbourg 14
Montreal 14
Redondo Beach 14
Brooklyn 13
Johannesburg 13
Shanghai 13
Catania 12
Porto Alegre 12
Tianjin 12
Boston 11
Chennai 10
Belo Horizonte 9
Haiphong 9
Mumbai 9
Palermo 9
Tokyo 9
Warsaw 9
Da Nang 8
Poplar 8
Stockholm 8
Brasília 7
Dhaka 7
Düsseldorf 7
Helsinki 7
Houston 7
Lima 7
Paris 7
Santo André 7
Seattle 7
Tunis 7
Baghdad 6
Denver 6
Nova Iguaçu 6
Phoenix 6
San Francisco 6
San José 6
Tashkent 6
The Dalles 6
Baku 5
Bexley 5
Franca 5
Naples 5
Natal 5
New Delhi 5
Shenzhen 5
São José dos Campos 5
Ankara 4
Bauru 4
Curitiba 4
Guarulhos 4
Istanbul 4
Jakarta 4
Kingston 4
Kuala Lumpur 4
Lahore 4
Las Vegas 4
Limina 4
London 4
Manchester 4
Panama City 4
Philadelphia 4
Quito 4
Toronto 4
Trapani 4
Barretos 3
Bắc Ninh 3
Campinas 3
Caracas 3
Davenport 3
Dublin 3
Totale 2.826
Salva come PNG Salva come JPEG
Nome #
Modeling the Bone Marrow Niche in Multiple Myeloma: From 2D Cultures to 3D Systems 171
Influence of Vitamin D and Its Analogues in Type-B Lymphomas 118
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 112
Highlights on the Effects of Non-Coding RNAs in the Osteonecrosis of the Jaw 111
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML 103
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey 99
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 98
Oxidative Stress and Chronic Myeloid Leukemia: A Balance between ROS-Mediated Pro- and Anti-Apoptotic Effects of Tyrosine Kinase Inhibitors 94
Using Artificial Intelligence to Enhance Myelodysplastic Syndrome Diagnosis, Prognosis, and Treatment 92
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 90
BCR-ABL nuclear entrapment kills human CML cells: Ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B 87
Gut Microbiota Dysbiosis and Dietary Interventions in Non-Hodgkin B-Cell Lymphomas: Implications for Treatment Response 86
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 85
Bispecific Antibodies and Antibody–Drug Conjugates in Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma, Focusing on Diffuse Large B-Cell Lymphoma 84
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 84
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: The NEXT-in-CML study 83
Retinal Vessel Analysis and Microvascular Abnormalities in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms 82
No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level 81
A case of high-risk AML in a patient with advanced systemic mastocytosis 80
Targeting chronic myeloid leukemia stem/progenitor cells using venetoclax-loaded immunoliposome 79
Navigating the Landscape of Exosomal microRNAs: Charting Their Pivotal Role as Biomarkers in Hematological Malignancies 78
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 77
DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications 77
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 76
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 76
Chronic Myeloid Leukemia and the T315I BCR::ABL1 Mutation 75
Utilization of Machine Learning in the Prediction, Diagnosis, Prognosis, and Management of Chronic Myeloid Leukemia 74
A Treatment-free Interval Allowed by Ponatinib as Fourth-line Therapy 73
Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey 71
All-trans-retinoic-acid- and growth-factor-mediated induction of alkaline phosphatase activity in freshly isolated chronic myeloid leukemia cells 71
Decoding Immunodeficiencies with Artificial Intelligence: A New Era of Precision Medicine 70
Acute myeloid leukemia occurring in a patient with polycythemia vera in treatment with hydroxyurea [5] 70
Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells 69
Hematological Malignancies in Older Patients: Focus on the Potential Role of a Geriatric Assessment Management 69
All-trans retinoic acid might also induce apoptosis in freshly isolated chronic myeloid leukemia cells 68
Curcumin and Acute Myeloid Leukemia: Synergistic Effects with Targeted Therapy 66
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint 66
Biochemical fingerprinting of dried blood serum from chronic lymphocytic leukemia patients by Raman spectroscopy: Towards prognostic classification 64
Septic Shock in Hematological Malignancies: Role of Artificial Intelligence in Predicting Outcomes 63
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy 61
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan 59
Bone Marrow Edema and Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia 59
The Q-LAMP method represents a valid and rapid alternative for the detection of the BCR-ABL1 rearrangement in Philadelphia-positive Leukemias 58
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib 57
Aberrant phenotypic expression of the T-cell-associated antigen CD8 on B-cell chronic lymphocytic leukemia cells 57
Nilotinib 300 mg twice daily: An academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients 54
Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up 54
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 53
Utility of flow cytometry as a screening tool for transplant donors for chronic lymphocytic leukemia 52
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia 51
Chk1 inhibition restores inotuzumab ozogamicin citotoxicity in CD22-positive cells expressing mutant p53 49
CD34 expression in adult acute lymphoblastic leukemia 48
Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib 47
Uncommon long-term survival in a patient with chronic myeloid leukemia 46
Cutaneous vasculitis in non Hodgkin's lymphoma 45
T cell receptor δ-chain gene rearrangement in a novel case of adult NK cell leukemia 44
null 43
Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia 42
Dasatinib first-line: Multicentric Italian experience outside clinical trials 42
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 41
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study 41
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 39
Real‐World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi‐Resistant Chronic Phase Chronic Myeloid Leukemia (CML‐CP) Patient Population 39
Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study 37
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network 36
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 36
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib 36
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions 35
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 34
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 33
Oxidative Stress and Mitochondrial Dysfunction in Myelodysplastic Syndrome: Roles in Development, Diagnosis, Prognosis, and Treatment 32
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study 32
Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database 31
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 31
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 30
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 30
Integrated genomic, functional, and prognostic characterization of atypical chronic myeloid leukemia 29
Efficacy of dasatinib in a very elderly CML patient expressing a rare E13A3 BCR-ABL1 fusion transcript: A case report 29
Infliximab therapy in hematologic malignancies: Handle with care (Comment) 28
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients 27
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors 27
Efficacy of nilotinib in a CML patient expressing the three-way complex variant translocation t(2;9;22) 27
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report 27
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia 27
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) 26
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 26
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection 26
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 25
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 25
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network 24
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 23
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 23
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 23
Myeloid Derived Suppressor Cells (MDSCs) are increased and exert immunosuppressive activity together with Polymorphonuclear Leukocytes (PMNs) in chronic myeloid leukemia patients 22
Second-line dasatinib therapy improved compliance and deep molecular responses in imatinib-intolerant chronic myeloid leukemia patients 21
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment 21
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2‑OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 21
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up 21
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study 21
Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia 20
Totale 5.475
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.062
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.062
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202429 0 0 0 0 0 0 0 0 0 11 2 16
2024/20251.149 20 0 0 24 54 17 149 137 264 81 126 277
2025/20264.439 146 223 229 314 361 876 361 556 612 346 259 156
2026/2027536 169 367 0 0 0 0 0 0 0 0 0 0
Totale 6.153